Skip to NavigationSkip to content

Manufacturing and Production

LogiPharma/LogiMed Virtual Event Exclusively For Supply Chain & Logistics Innovators

DIA Global Annual Meeting 2021

CPhI Discover 2021

Optimization of design transfer from device development to final assembly

Julie Beeso joins Envision Pharma Group as new Global Director

Published on: 18/01/22
Global Director
Envision Pharma Group

Envision Pharma Group has appointed Julie Beeso as its Global Director, Professional Development and Engagement. Julie has worked for almost 25 years across different medical comunications roles in the UK and US, and her expertise will be used to execute a professional development and talent management strategy for Envision Scientific Solutions (ESS).

Mario Torchia appointed as new Vice President of Sales & Marketing at InSilicoTrials

Published on: 18/01/22
Vice President of Sales & Marketing

InSilicoTrials, a leader in simulation software solutions for healthcare, has announced Mario Torchia’s appointment. Torchia recently led the Sales Strategy as Delmia Geo Leader for South Europe at Dassault Systemes. At InSilico Trials, he will lead the Sales and marketing team, utilising his strategic market vision.

Enhertu granted priority review in US for patients with HER2-positive metastatic breast cancer

Enhertu, manufactured by AstraZeneca and Daiichi Sankyo, has been accepted for the treatment of adult patients in the US with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen. The application has also been granted Priority Review.

The FDA grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available options by demonstrating safety or efficacy improvements, preventing serious conditions, or enhancing patient compliance.

SMC accept Enhertu for the treatment of HER2 positive metastatic breast cancer

Daiichi Sankyo and AstraZeneca have announced that the SMC has accepted Enhertu® for use within NHS Scotland for the treatment of HER2 positive unresectable or metastatic breast cancer. The cancer treatment is approved for adults who have received two or more prior anti-HER2 based therapies, in line with its conditional marketing authorisation.

Almirall and IRB Barcelona research for skin disease therapeutics discovery

Almirall and IRB Barcelona (the Institute for Research in Biomedicine) have announced a research collaboration to identify the new oral treatments for immune-inflammatory skin diseases with remaining high unmet medical needs.

The collaboration aims to meet these needs using a novel therapeutic modality, called molecular glue degraders. These could represent an opportunity to expand the scope of druggable targets with small, drug-like molecules, that can reprogram natural cellular mechanisms to selectively remove disease driving proteins from human tissues.

Abbisko Therapeutics collaborates with Lilly to discover novel molecules

Abbisko Therapeutics announced that it has entered into a partnership and exclusive licensing agreement with Eli Lilly and Company. This collaboration is focused on the further discovery, development, and potential commercialisation of novel molecules against an undisclosed target for cardiometabolic diseases with critical unmet needs.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches